Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease.
García-Alberca JM, De La Guía P, Gris E, Mendoza S, López De La Rica M, López-Trigo JA, López-Mongil R, García-López T, López-García R, Rodríguez Del Rey T, Gay-Puente J, García-Castro J, Casales F, Morato X, Boada M, González-Velasco G, Marín-Carmona JM, Páez NI, León M, Carrillejo R, Rius F, Barbancho MÁ, Lara JP, Blanco-Reina E.
García-Alberca JM, et al. Among authors: de la guia p.
J Alzheimers Dis. 2024 Nov 5:13872877241292018. doi: 10.1177/13872877241292018. Online ahead of print.
J Alzheimers Dis. 2024.
PMID: 39501608